Open AccessLong-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events
Author(s) -
Marc P. Bonaca,
Deepak L. Bhatt,
Ton Oude Ophuis,
Philippe Gabríel Steg,
Robert F. Storey,
Marc Cohen,
Julia Kuder,
KyungAh Im,
Giulia Magnani,
Andrzej Budaj,
Pierre Théroux,
Christian Hamm,
Jindřich Špinar,
Róbert Gábor Kiss,
Anthony J. Dalby,
Félix Medina,
Frederic Kontny,
Philip E. Aylward,
Eva C. Jensen,
Peter Held,
Eugene Braunwald,
Marc S. Sabatine
Publication year - 2016
Publication title -
jama cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.108
H-Index - 63
eISSN - 2380-6591
pISSN - 2380-6583
DOI - 10.1001/jamacardio.2016.1017
Subject(s) - ticagrelor , medicine , discontinuation , tolerability , myocardial infarction , timi , adverse effect , stroke (engine) , placebo , aspirin , acute coronary syndrome , cardiology , percutaneous coronary intervention , mechanical engineering , engineering , pathology , alternative medicine
In the PEGASUS-TIMI 54 trial, treatment with ticagrelor reduced the incidence of cardiovascular death, myocardial infarction, or stroke by 15% to 16% among stable patients compared with placebo. However, more patients prematurely discontinued treatment with ticagrelor than with placebo.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom